Blueprint Medicines, Novo Nordisk A/S, BlackRock, Venture Global, SpringWorks Therapeutics, Blackstone, and Welltower are the seven Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies expected to increase their earnings and revenues at significantly faster rates than the overall market. Rather than paying out large dividends, these firms typically reinvest profits into research, development, and expansion, which can lead to higher valuations—and also greater volatility and risk. These companies had the highest dollar trading volume of any Growth stocks within the last several days.
Blueprint Medicines (BPMC)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Shares of NASDAQ:BPMC traded up $0.42 during midday trading on Wednesday, reaching $128.02. 7,465,810 shares of the company's stock were exchanged, compared to its average volume of 1,075,745. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company's 50 day simple moving average is $93.17 and its two-hundred day simple moving average is $95.16. Blueprint Medicines has a 12 month low of $73.04 and a 12 month high of $128.15. The firm has a market capitalization of $8.27 billion, a PE ratio of -118.54 and a beta of 0.83.
Read Our Latest Research Report on BPMC
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
NYSE:NVO traded up $1.85 during mid-day trading on Wednesday, hitting $72.76. The company's stock had a trading volume of 4,490,776 shares, compared to its average volume of 6,849,353. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average of $65.62 and a 200-day moving average of $81.15. The company has a market capitalization of $326.51 billion, a price-to-earnings ratio of 22.12, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.
Read Our Latest Research Report on NVO
BlackRock (BLK)
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.
Shares of BlackRock stock traded up $5.10 during midday trading on Wednesday, hitting $987.23. 190,455 shares of the company were exchanged, compared to its average volume of 687,639. The firm has a 50 day simple moving average of $922.81 and a 200-day simple moving average of $974.15. BlackRock has a 52 week low of $752.30 and a 52 week high of $1,084.22. The firm has a market cap of $152.95 billion, a P/E ratio of 23.51, a PEG ratio of 1.90 and a beta of 1.41. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.23 and a quick ratio of 5.23.
Read Our Latest Research Report on BLK
Venture Global (VG)
Venture Global has fundamentally reshaped the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. Our innovative and disruptive approach, which is both scalable and repeatable, allows us to bring LNG to a global market years faster and at a lower cost.
Venture Global stock traded up $1.03 during mid-day trading on Wednesday, hitting $15.31. 11,065,927 shares of the company were exchanged, compared to its average volume of 7,777,379. The business has a fifty day moving average of $9.52. Venture Global has a 1-year low of $6.75 and a 1-year high of $25.50.
Read Our Latest Research Report on VG
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of SWTX traded down $0.01 during trading hours on Wednesday, hitting $46.74. The stock had a trading volume of 3,299,050 shares, compared to its average volume of 4,042,031. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -13.43 and a beta of 0.77. The company's fifty day moving average is $43.27 and its two-hundred day moving average is $43.35. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $62.00.
Read Our Latest Research Report on SWTX
Blackstone (BX)
Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.
Blackstone stock traded down $0.20 during trading hours on Wednesday, hitting $138.81. 999,665 shares of the stock were exchanged, compared to its average volume of 3,780,248. Blackstone has a 12 month low of $115.66 and a 12 month high of $200.96. The business's 50-day moving average is $135.55 and its two-hundred day moving average is $158.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.71 and a current ratio of 0.67. The stock has a market capitalization of $101.28 billion, a P/E ratio of 38.24, a P/E/G ratio of 1.07 and a beta of 1.67.
Read Our Latest Research Report on BX
Welltower (WELL)
Welltower Inc. NYSE: WELL, a real estate investment trust ("REIT") and S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. Welltower invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people's wellness and overall health care experience.
WELL stock traded up $0.29 during midday trading on Wednesday, reaching $152.49. 840,238 shares of the company's stock traded hands, compared to its average volume of 2,904,958. The company has a 50-day simple moving average of $148.06 and a two-hundred day simple moving average of $141.54. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 0.48. Welltower has a 1-year low of $100.13 and a 1-year high of $158.55. The company has a market cap of $99.72 billion, a price-to-earnings ratio of 97.75, a PEG ratio of 2.87 and a beta of 0.94.
Read Our Latest Research Report on WELL
Featured Articles
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
